top of page


MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
Agreement to support future studies investigating the combination of ateganosine and atezolizumab for safe and effective cancer...


NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company commercializing the Monarch...


NeuroSigma Announces New Clinical Trial of Monarch eTNS System for Treatment of ADHD in Children with Fetal Alcohol Syndrome at UCLA
Trial to be conducted at UCLA and funded by a grant from National Institute on Alcohol Abuse and Alcoholism (NIAAA) First phase of trial...
Press
bottom of page